Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)

Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)

The most appropriate duration of anticoagulant treatment for cancer-associated venous thromboembolism (CAT) remains unclear. We have conducted a prospective multicenter study in CAT patients with more than 6 months of anticoagulant treatment to predict the risk of venous thromboembolism (VTE) recurr...

Full description

Bibliographic Details
Main Authors: Remedios Otero, Aurora Solier-López, Verónica Sánchez-López, Julia Oto, Elena Arellano, Samira Marín, Luis Jara-Palomares, Teresa Elías, María Isabel Asencio, Isabel Blasco-Esquivias, María Rodríguez de la Borbolla, José María Sánchez-Díaz, Macarena Real-Domínguez, Emilio García-Cabrera, Francisco Javier Rodríguez-Martorell, Pilar Medina
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
biomarkers
venous thromboembolism
recurrence
cancer
cancer-associated thrombosis
Online Access:https://www.mdpi.com/2072-6694/14/11/2771

Internet

https://www.mdpi.com/2072-6694/14/11/2771

Similar Items